The statistics reported in table are calculated extrapolations of various prevalence or incidence rates against the populations of a particular country or region. The statistics used for prevalence/incidence of Migraine are typically based on US, UK, Canadian or Australian statistics. This extrapolation calculation is automated and does not take into account any genetic, cultural, environmental, social, racial or other differences across the various countries and regions for which the extrapolated Migraine statistics below refer to. As such, these extrapolations may be inaccurate and only give a general indication as to the actual prevalence or incidence of Migraine in that region.

The word ‘prevalence’ of Migraine usually means the estimated population of people who are managing Migraine at any given time (i.e. people with Migraine).

The term ‘incidence’ of Migraine means the annual diagnosis rate, or the number of new cases of Migraine diagnosed each year (i.e. getting Migraine).

Hence, these two statistics types can differ: a short disease like flu can have high annual incidence but low prevalence, but a life-long disease like diabetes has a low annual incidence but high prevalence.

Prevalence of Migraine: 28
In the statutes of the Spanish Neurology Society (SEN) it is set out that the Research Groups are scientific parts of the SEN whose purpose is the deepening of research, assistance and study in the various areas of neurology. GESCEN is the SEN's Research Group on Headache. This Research Group is made up of approximately 200 neurologists with a special interest in the wide area of head pain. GESCEN spreads its efforts over three basic areas: assistance, training and research:

**Assistance:** The creation of surgeries and headache units is markedly improving the quality of assistance available to these patients. Also, this work is made easier by the support of research groups from other scientific societies, like SEMFYC or SEMERGEN.

**Training:** Every year, GESCEN organises a Headache Course for neurology residents which is always a success both in terms of assistance and participation. Each 2-3 years the ‘Recommendations of the SEN Research Group on Headache’ are published, this being a small manual of some 100 pages, which is an obligatory reference document. The number of talks and lectures covering headache which many members of GESCEN have given in Health Centres, Hospitals and other forum audiences is counted by the hundred and certainly reaches the thousands. Every year there are training symposia on concrete aspects of headache, led by members of this Research Group. In the Annual Meeting of the SEN, in addition to scientific reports, a morning is reserved to go into new ideas and controversies related to headaches. And since a year ago, GESCEN organises joint training courses with International Scientific Organisations.

**Research:** The number of presentations in national and international conferences given by members of GESCEN grows from year to year. The same can be said of publications in medical journals. For some time GESCEN’s membership has included internationally recognised experts and the next congress of the European Headache Federation will be held in Valencia in 2006 under the presidency of a Spaniard, Dr José Miguel Láinez.

http://www.cefaleas.sen.es/que.htm

European Migraine Patients Call to Action

(continue from page 1)

...ting the burden and impact migraine has on the life of the patient. Issues taken into consideration included interference with a patient's family, career, general health and sex-life.

Results from this on-line survey reveal that migraine seriously impinges on a sufferer's ability to perform general everyday activities. One-third of patients experience attacks more than 30 days per year lasting more than 12 hours per week.

The Call to Action will be used by patient groups locally and at European level to further raise awareness of migraine issues among professionals, policy makers, employers and the public. It concentrates specifically on the important issues of:

- Rights and responsibilities
- Educating and raising awareness
- Patient healthcare and professional dialogue
- Migraine control and prevention

You can download a copy of the full document below. A hard copy is available by contacting us at 1850 200378 or by email to info@migraine.ie. http://www.migraine.ie/
Dear Colleagues,

The organizing committee of the 8th (European Headache Federation) EHF Congress is pleased to invite you to submit an abstract to the congress describing original research in the fields related to headache.

With plenary lectures by eminent headache specialists from over 16 countries covering a variety of topics, symposia, debates, scientific sessions and a clearly recognizable programme for European General Practitioners we are confident that The 8th EHF congress will provide you with a unique opportunity for which to present your research to a truly international audience. Please visit the congress website at http://www.ehf-org.org/8ehf/call.asp and follow the instructions for submission.

Finally we would like to draw your attention to the extensive travel and information guide we have compiled on Valencia, host city for The America’s Cup, at http://www.ehf-org.org/8ehf/vallencia.asp. We sincerely hope that you will be able to join us in Valencia in April 2006, a truly inspirational city for what will be a truly inspirational and stimulating congress.

Sincerely Yours

Congress Secretariat
EHF NEWS

Editor: F. Antonaci (Pavia)
Co-editor: E. Couturier (Amsterdam)
Legal Director: S. Angeletti (Milan)
Registration n° 464/1996
Publisher: Tipografia Viscontea, Pavia, Italy

EHF Newsletter is published bimonthly by the European Headache Federation, whose business offices are located at the Department of Neurological Sciences “C. Mondino” Foundation, University of Pavia, Via M. Mondino 2, 27100, Pavia, Italy (neuronet@libero.it).

Purpose: EHF Newsletter, a European Headache Federation publication, is dedicated to increasing physicians' awareness by educating and informing them as to what is going on in the field of headache in Europe.

This newsletter seeks to provide timely and accurate information from the most knowledgeable sources. The newsletter is mailed to EHF members, national drug companies and medical journals in line with information given by board members. The views expressed in the articles in EHF News are those of the authors and do not necessarily reflect those of the EHF and the Publisher.

What's on...What's on...What's on...

PRESIDENT
• M. Lainez (Valencia)
1st VICE-PRESIDENT
• H. Diener (Essen)
2nd VICE-PRESIDENT
• F. Antonaci (Pavia)
PAST PRESIDENT
• P. Saxena (Rotterdam)
GENERAL SECRETARY
• E. Couturier (Amsterdam)
TREASURER
• R. Agosti (Zurich)
MEMBERS AT LARGE
• J. Afra (Budapest)
• M. Färkkilä (Helsinki)
• D. Obelieniene (Kaunas)
• D. Valade (Paris)

European Headache Federation is incorporated in England and Wales as a company limited by guarantee; registered charity no. 1084181

European migraines: how many we are ?
(continue from page 1)

Migraine in Europe (Extrapolated Statistics)

<table>
<thead>
<tr>
<th>Country</th>
<th>Population</th>
<th>Migraine Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>8,174,762</td>
<td>841,519</td>
</tr>
<tr>
<td>Belgium</td>
<td>10,348,276</td>
<td>1,065,263</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>60,270,708</td>
<td>6,204,337</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>1,024,178</td>
<td>128,283</td>
</tr>
<tr>
<td>Denmark</td>
<td>3,413,392</td>
<td>357,260</td>
</tr>
<tr>
<td>Finland</td>
<td>5,214,512</td>
<td>536,788</td>
</tr>
<tr>
<td>Greece</td>
<td>10,424,213</td>
<td>1,096,069</td>
</tr>
<tr>
<td>Germany</td>
<td>8,242,609</td>
<td>8,484,886</td>
</tr>
<tr>
<td>Ireland</td>
<td>3,969,558</td>
<td>408,630</td>
</tr>
<tr>
<td>Italy</td>
<td>8,986,400</td>
<td>8,976,505</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>462,690</td>
<td>47,629</td>
</tr>
<tr>
<td>Monaco</td>
<td>3,270</td>
<td>1,321</td>
</tr>
<tr>
<td>Netherlands</td>
<td>6,318,199</td>
<td>1,679,814</td>
</tr>
<tr>
<td>Poland</td>
<td>8,626,349</td>
<td>5,976,241</td>
</tr>
<tr>
<td>Portugal</td>
<td>10,524,145</td>
<td>1,083,367</td>
</tr>
<tr>
<td>Spain</td>
<td>8,208,780</td>
<td>1,146,550</td>
</tr>
<tr>
<td>Sweden</td>
<td>8,986,400</td>
<td>925,070</td>
</tr>
<tr>
<td>Switzerland</td>
<td>7,450,867</td>
<td>767,001</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>8,270,708</td>
<td>6,204,337</td>
</tr>
<tr>
<td>Wales</td>
<td>2,918,900</td>
<td>300,382</td>
</tr>
</tbody>
</table>

Prevalence Rate for Migraine: approx 1 in 9 or 10.29% or 28 million people in USA.

Extrapolation of Prevalence Rate of Migraine to Countries and Regions: The following table attempts to extrapolate the above prevalence rate for Migraine to the populations of various countries and regions. As discussed above, these prevalence extrapolations for Migraine are only estimates and may have limited relevance to the actual prevalence of Migraine in any region.

What’s on...What’s on...What’s on...

· 10-12 March 2006, Copenhagen, Denmark
15th International Headache Research Seminar
Information: http://www.ihrs.dk
hagn@glostruphosp.kbhamt.dk

· 30 June-1° July 2006, Glasgow, Great Britain
VII International Congress on Headache in Children and Adolescents
Information: www.ICHCA2006.org
denise@conference2k.com

· 5th-7th October 2006, Castrocaro Terme (FC), Italy
European Headache Federation School, 2006 course (International School on Adaptive Disorders and Headache)
Information: neuronet@libero.it